Mitoxantrone treatment in patients with early relapsing-remitting multiple sclerosis

Abstract

We investigated the clinical and MRI effects of mitoxantrone (MITOX) administered to 45 patients during the first five years of highly active relapsing-remitting multiple sclerosis. Differences occurring between the end of treatment and follow-up (clinical mean: 3.6 years; brain MR: 1.8 years) with respect to baseline variables (EDSS, annualized relapse rate, active T2 lesions, new T1 lesions and number of Gd-enhancing lesions) were analysed using parametric and non-parametric tests. One patient developed leukemia four months after the end of the treatment; no other serious adverse events occurred during treatment and the follow-up period. A clinically relevant reduction in the annualized relapse rate ( P < 0.0001 at end of treatment and P < 0.0001 at follow-up) and improvement in the EDSS (P < 0.0001 at end of treatment and P = 0.0005 at follow-up) was found. At the end of treatment, 53% of patients experienced no increase in active T2 lesions, while 73% showed no increase in the number of new T1 lesions. At follow-up, 41 out of 45 (91%) patients showed a stable MRI pattern and were active-scan free. Despite potential serious adverse events, MITOX may be considered an option in selected patients with very active early MS. Multiple Sclerosis 2007; 13: 975—980. http://msj.sagepub.com

Keywords

brain MRI disability early stage mitoxantrone multiple sclerosis

Get full access to this article

View all access options for this article.

References

Bjartmar C. , Wujek JR , Trapp BD Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J Neurol Sci 2003; 206: 165—71.

Lycklama à Nijeholt G. , Barkhof F. Differences between subgroups of MS: MRI findings and correlation with histopathology. J Neurol Sci 2003; 206: 173—74.

Goodin DS , Arnason BG , Coyle PK , Frohman EM , Paty DW The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis . Neurology 2003; 61: 1332—38.

Rizvi SA , Zwibel H. , Fox EJ Mitoxantrone for multiple sclerosis in clinical practice. Neurology 2004; 63: S25—S27.

McDonald WI , Compston A. , Edan G. et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121—27.

Rio J. , Nos C. , Tintore M. , Tellez N. , Galan I. , Pelayo R. et al. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann Neurol 2006 ; 59: 344—52.

Tomassini V. , Paolillo A. , Russo P. , Giugni E. , Prosperini L. , Gasperini C. et al. Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis. J Neurol 2006; 253: 287—93.

Smith IE Mitoxantrone (novantrone): a review of experimental and early clinical studies . Cancer Treat Rev 1983; 10: 103—15.

Filippi M. , Horsfield MA , Ader HJ , Barkhof F. , Bruzzi P. , Evans A. et al. Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis . Ann Neurol 1998; 43: 499—506.

10.

Li DK , Zhao GJ , Paty DW ; University of British Columbia MS/MRI Analysis Research Group. The SPECTRIMS Study Group.Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results. Neurology 2001 ; 56: 1505—13.

11.

Norman GR , Streiner DL Biostatistica. Ambrosiana, 2000: 155—156.

12.

Ledda A. , Caocci G. , Spinicci G. , Cocco E. , Mamusa E. , La NasaG. Two new cases of acute promyelocytic leukemia following mitoxantrone treatment in patients with multiple sclerosis. Leukemia 2006; 20: 2217—18.

13.

Weinshenker BG , Bass B. , Rice GP , Noseworthy J. , Carriere W. , Baskerville J. et al. The natural history of multiple sclerosis: a geographically based study. 2. Predicting value of early clinical course . Brain 1989; 112: 1419—28.

14.

Lublin FD , Baier M. , Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis . Neurology 2003; 61: 1528—32.

15.

Kantarci OH , Weinshenker BG Natural history of multiple sclerosis. Neurol Clin 2005; 23: 17—38.

16.

Edan G. , Miller D. , Clanet M. , Confavreux C. , Lyon-Caen O. , Lubetzki C. et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997; 62: 112—18.

17.

Millefiorini E. , Gasperini C. , Pozzilli C. , D'Andrea F. , Bastianello S. , Trojano M. et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 1997; 244: 153—59.

18.

Hartung HP , Gonsette R. , Konig N. , Kwiecinshi H. , Guseo A. , Morrissey SP et al. Mitoxantrone in Multiple Sclerosis Study Group (MIMS). Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002; 360: 2018—25.

19.

Edan G. , Morrissey S. , Le Page E. Rationale for the use of mitoxantrone in multiple sclerosis. J Neurol Sci 2004; 223: 35—39.

20.

Zingler VC , Nabauer M. , Jahn K. , Gross A. , Hohlfeld R. , Brandt T. , Strupp M. Assessment of potential cardiotoxic side effects of mitoxantrone in patients with multiple sclerosis. Eur Neurol 2005; 54: 28—33.